HIGHLIGHTS
- who: Waseem Chauhan and Rahima Zennadi from the Division of Hematology, Duke Comprehensive Sickle Cell Center, Department of Medicine, Duke University School of Medicine, Research Drive, Durham, NC, USA have published the Article: Keap1-Nrf2 Heterodimer: A Therapeutic Target to Ameliorate Sickle Cell Disease, in the Journal: Antioxidants 2023, 12, 740. of /2023/
- what: The cyclic polymerization and depolymerization of HbS are the hallmark of SCD, causing oxidative stress.
SUMMARY
A genomewide chromatin immunoprecipitation (ChIP)-seq has suggested that the Nrf2/Keap1- antioxidant response element (ARE) signaling pathway is highly sensitive . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.